{"favorite_id": 3312, "calc_type": "calculator", "dosing": false, "full_title_en": "Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes", "short_title_en": "mGPS for Cancer Outcomes", "medium_description_en": "Provides improved cancer prognosis over the <calculator id=\"3311\">original score</calculator>, based on serum biomarkers.", "short_description_en": "Cancer prognosis based on biomarkers.", "before_use": "", "instructions_en": "<p>We recommend this modified version of the score over the <calculator id=\"3311\">original GPS</calculator>.</p>", "slug": "modified-glasgow-prognostic-score-mgps-cancer-outcomes", "logic_language": "javascript", "md5": "cb0bf1bb526441e77554c5f27eb86a81", "cmeVersion": null, "cmeReleaseDate": null, "cmeEndDate": null, "cmeLastReviewed": null, "publishedAt": "2022-04-21T20:29:15.046Z", "vuid": "63b0fa6d-429f-4c39-ad9f-5b659cc0f3fa", "versionNumber": 1, "isVisibleInListView": true, "disabled": false, "replacement_calc_id": null, "disabled_reason": null, "search_abbreviation_en": ["Crp", "alb", "mgps", "glasgow", "cancer", "CA"], "seo": {"meta_description_en": "The Modified Glasgow Prognostic Score uses biomarkers to indicate systemic inflammatory response previously associated with poor prognoses in cancer.", "keywords_en": "Gps, cancer, colorectal, renal, CA, alb, crp, glasgow, cancer prognosis, albumin, modified, mgps, glasgow modified, glasgow cancer"}, "content": {"reviewer": {"expert_name": []}, "related_resources": {"videos": [], "sdm_tool": [], "teaching": [], "interests": [], "guidelines": [], "mdcalc_rating": [], "partner_contact": []}, "how_to_use": {"use_case_en": "<p>Patients with known cancer.</p>", "pearls_pitfalls_en": "<ul>\n<li>The Modified Glasgow Prognostic Score (mGPS) has been evaluated across numerous different cancer cohorts and suggests incrementally worsening prognosis with increasing score.</li>\n<li>Depending upon patient selection, stage, cancer and other factors the resulting survival numbers vary widely.</li>\n<li>The modified GPS uses the same parameters as the <calculator id=\"3311\">original GPS</calculator> (CRP and albumin), but weighs the inflammatory component more heavily; i.e., patients with low albumin are still assigned a score of 0 even if CRP is elevated. This modification was shown to have better correlation with survival (in colon and rectal cancer from the original paper, and in other cancers from the validation papers).</li>\n</ul>", "why_use_en": "<p>Multiple studies suggest significantly worse outcome in multiple types of cancer, including &ldquo;increased weight loss, poor performance status, increased comorbidity, increased pro-inflammatory and angiogenic cytokines and complications on treatment.&rdquo; (<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/17245566\" target=\"_blank\" rel=\"noopener\">McMillan DC 2013</a>)</p>"}, "next_steps": {"advice_en": "<p>The Modified Glasgow Prognosis Score helps stratify prognosis groups and may be a worthy addition to multifactorial evaluations. As a stand-alone in individual cases it is unclear at this point how accurate it is likely to be.</p>", "management_en": "<p>We are unaware of validated management algorithms using the mGPS.</p>", "critical_actions_en": "<p>The modified GPS does not assign a point for low albumin as a singular finding, which is different from the <calculator id=\"3311\">original GPS</calculator>. The c-reactive protein value must be elevated for points to be assigned.</p>"}, "about": {"formula_en": "<p>Selection of appropriate criteria.</p>", "more_info_en": "<p>The modified GPS uses the same parameters as the <calculator id=\"3311\">original GPS</calculator> (CRP and albumin), but weighs the inflammatory component more heavily; i.e., patients with low albumin are still assigned a score of 0 even if CRP is elevated. This modification was shown to have better correlation with survival (in colon and rectal cancer from the original paper, and in other cancers from the validation papers).</p>\n<p>The mGPS has been shown to be accurate in different types of cancer, including renal, lung, gastric cancers, as well as in primary care. The predictive values are listed below for each type of cancer.</p>\n<div class=\"table-responsive\">\n<table class=\"table table-bordered table-hover\">\n<tbody>\n<tr>\n<th>Type of cancer</th>\n<th>mGPS</th>\n<th>Median Survival</th>\n</tr>\n<tr>\n<td>Gastric</td>\n<td>0</td>\n<td>5 year Overall Survival: 74.6%</td>\n</tr>\n<tr>\n<td></td>\n<td>1</td>\n<td>5 year Overall Survival: 61.4%</td>\n</tr>\n<tr>\n<td></td>\n<td>2</td>\n<td>5 year Overall Survival: 34.6%</td>\n</tr>\n<tr>\n<td>Renal</td>\n<td>0</td>\n<td>1 year RFS: 90.9%</td>\n</tr>\n<tr>\n<td></td>\n<td>1</td>\n<td>1 year RFS: 61.1%</td>\n</tr>\n<tr>\n<td></td>\n<td>2</td>\n<td>1 year RFS: 10.1%</td>\n</tr>\n<tr>\n<td>Lung (Small Cell)</td>\n<td>0</td>\n<td>3 Month Survival: 99%</td>\n</tr>\n<tr>\n<td></td>\n<td>2</td>\n<td>3 Month Survival: 71%</td>\n</tr>\n</tbody>\n</table>\n</div>", "evidence_based_medicine_en": "<div class=\"authorimage\"><img style=\"max-width: 100%;\" src=\"https://cdn-web-img.mdcalc.com/mgps.png\" class=\"alignnone size-full wp-image-1839\" alt=\"mgps pi diagram\"></div>", "references_list": {"Validation": [{"text": "Nozoe T, Iguchi T, Egashira A, Adachi E, Matsukuma A, Ezaki T. Significance of modified Glasgow prognostic score as a useful indicator for prognosis of patients with gastric carcinoma. Am J Surg 2011;201(2):186\u2013191", "href": "https://www.ncbi.nlm.nih.gov/pubmed/20832047"}, {"text": "Tai CG, Johnson TV, Abbasi A, et al. External validation of the modified Glasgow prognostic score for renal cancer. Indian Journal of Urology\u202f: IJU\u202f: Journal of the Urological Society of India. 2014;30(1):33-37. doi:10.4103/0970-1591.124203.", "href": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897050/"}, {"text": "Simmons CP, et al. Prognosis in advanced lung cancer--A prospective study examining key clinicopathological factors.Lung Cancer. 2015 Jun;88(3):304-9. doi: 10.1016/j.lungcan.2015.03.020. Epub 2015 Mar 28.", "href": "https://www.ncbi.nlm.nih.gov/pubmed/25870155"}], "Outcomes": [], "Validations": [], "Original/Primary Reference": [{"text": "Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DS, Foulis AK et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 2011; 104(4):726\u2013734", "href": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049591/"}], "Other References": [{"text": "de Paula Pantano N, Paiva BS, Hui D, Paiva CE. Validation of the Modified Glasgow Prognostic Score in Advanced Cancer Patients Receiving Palliative Care. J Pain Symptom Manage. 2016 Feb;51(2):270-7. doi: 10.1016/j.jpainsymman.2015.09.010. Epub 2015 Oct 24.", "href": "https://www.ncbi.nlm.nih.gov/pubmed/26598040"}, {"text": " Proctor MJ, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer. 2011 Nov;47(17):2633-41. doi: 10.1016/j.ejca.2011.03.028. Epub 2011 Jul 1.", "href": "https://www.ncbi.nlm.nih.gov/pubmed/21724383"}], "Clinical Practice Guidelines": [], "Manufacturer Website": []}}, "creator": [{"qa_en": "", "approved": true, "name": "Dr. Donald McMillan", "creator_info": {"deceased": null, "about_en": "<p>Donald McMillan, MD, is a professor of surgical science at the University of Glasgow and an associate academic at the Institute of Cancer Sciences. His research focuses on systemic inflammatory response in weight loss and poor physical function, quality of life and survival of cancer patients.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-donald-mcmillan.jpeg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=McMillan+DC%5BAuthor%5D"}}, {"qa_en": "", "approved": false, "name": "Dr. Michael J. Proctor", "creator_info": {"deceased": null, "about_en": "<p>Michael J. Proctor, MD, is a faculty member at the University of Glasgow and practices at the Royal Infirmary. His research focuses on systemic inflammatory response in weight loss, poor physical function and quality of life and poor survival of the patient with cancer.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/default.jpeg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Proctor%20MJ%5Bauth%5D;"}}], "contributor": {"expert_name": []}}, "input_schema": [{"type": "radio", "name": "crp", "default": null, "show_points": false, "optional": false, "conditionality": "", "tips_en": "", "label_en": "CRP", "option_fhir_rules": null, "options": [{"label": "CRP \u226410 mg/L", "value": 1}, {"label": "CRP >10 mg/L", "value": 2}], "mdcalc_info_concept": null}, {"type": "radio", "name": "alb", "default": null, "show_points": false, "optional": false, "conditionality": "", "tips_en": "", "label_en": "Albumin", "option_fhir_rules": null, "options": [{"label": "Albumin <3.5 g/dL (35 g/L)", "value": 1}, {"label": "Albumin \u22653.5 g/dL (35 g/L)", "value": 2}], "mdcalc_info_concept": null}], "chief_complaint_en": ["Abdominal Pain", "Weakness"], "specialty_en": ["Family Practice", "Gastroenterology", "Hematology and Oncology", "Hepatology", "Hospitalist Medicine", "Internal Medicine", "Radiation Oncology"], "purpose_en": ["Prognosis"], "system_en": ["Gastrointestinal", "Oncologic"], "disease_en": ["Cancer", "Chemotherapy", "Pancreatic Cancer"], "tags": [], "versions": [], "related_calcs": [{"calcId": 3311, "short_title_en": "GPS for Cancer Outcomes", "slug": "glasgow-prognostic-score-gps-cancer-outcomes"}, {"calcId": 3313, "short_title_en": "Prognostic Index for Cancer", "slug": "prognostic-index-cancer-outcomes"}, {"calcId": 3315, "short_title_en": "Khorana Risk Score for VTE", "slug": "khorana-risk-score-venous-thromboembolism-cancer-patients"}]}